title: [Estimation of antioxidative effect of atorvastatin and fluvastatin used in primary prevention of coronary heart disease--effect on antioxidative enzymatic activity].
abstract: The effect of atorvastatin and fluvastatin on antioxidative enzymatic activity was studied in CHD risk patients. The study comprised 35 patients (20 men and 15 women) aged 35-47 years, who were allotted into two groups: I--18 patients were administered fluvastatin (Lescol) in a dose of 40 mg once daily at bed time for 6 weeks and II--17 patients were administered atorvastatin (Sortis) in a dose of 10 mg once daily at bed time for 6 weeks. The control group consisted of 12 clinically healthy subjects, aged 34-42 years. SOD-1, GSH-Px and CAT activity in erythrocytes was measured. Greater increase of low erythrocyte antioxidative enzymatic activity was observed in atorvastatin than in fluvastatin group.
authors.affiliation: Z Katedry Rehabilitacji z Klinika Chorób Wewnetrznych i Rehabilitacji Kardiologicznej, Uniwersytetu Medycznego, Lodzi.
authors.forename: Jan
authors.initials: J
authors.lastname: Kowalski
authors.forename: Lucjan
authors.initials: L
authors.lastname: Pawlicki
authors.forename: Joanna
authors.initials: J
authors.lastname: Grycewicz
authors.forename: Jan
authors.initials: J
authors.lastname: Błaszczyk
authors.forename: Robert
authors.initials: R
authors.lastname: Irzmańiski
authors.forename: Tomasz
authors.initials: T
authors.lastname: Ceglińiski
authors.forename: Edward
authors.initials: E
authors.lastname: Kowalczyk
authors.forename: Beata
authors.initials: B
authors.lastname: Liban-Gałka
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000378:metabolism*; D000069059:Atorvastatin; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control*; D004912:Erythrocytes / Q000187:drug effects / Q000201:enzymology; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage*; D005260:Female; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention; D011758:Pyrroles / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077340:Fluvastatin; D000069059:Atorvastatin